Improved lung function using a therapeutic educational multidisciplinary program in a pediatric cystic fibrosis clinic by Kernen, Yann et al.
Educ Ther Patient/Ther Patient Educ 2013; 5(1): 131-136




Improved lung function using a therapeutic educational
multidisciplinary program in a pediatric cystic fibrosis clinic
Yann Kernen1, Claudine Durussel1, Pierluigi Ballabeni2, Gaudenz Martin Hafen1
1 Division of Respiratory Medicine, Department of Pediatrics, University Hospital Lausanne, Switzerland
2 Institute of Social and Preventive Medicine (IUMSP), University Hospital Lausanne, and University of Lausanne, Switzerland
(Received 25 May 2012, accepted 14 November 2012)
Abstract – Background: Pulmonary disease remains the most common cause of morbidity and mortality in cystic
fibrosis. The clearing of mucus by chest physiotherapy is a major keystone of treatment. Daily therapy is time consum-
ing, with respiratory therapy, inhalation therapy and a lot of medications to be taken all day long. Treatment burden
becomes always a reason for intra-familial conflicts and stress. Adherence to treatment is a main issue, and influences
the eﬃciency of physiotherapy and inhalation Objective: The objective was to implement and evaluate TPE in a pedi-
atric cystic fibrosis consultation. Method: Open interventional study in patient ≥6 years of age. Patients were followed
on their regular 3-month basis over 2 years. Interventional education by cystic fibrosis physician and nurse took place
at each visit with assessment once yearly. At visit 1, a contract defining the content of the educational program was dis-
cussed. Primary endpoint: Evolution of FEV1 and FEF25-75%. Secondary endpoint: Evaluation of disease knowledge
and quality of life (CFQr©). At the end of the study we tested the knowledge about nutritional aspects of the disease in
the study group. Results: Out of 32 patients from 6 to 16 years, 17 accepted the study. FEV1% predicted increased 5.3%
in the intervention group. Conclusion: Using TPE, there is a clear trend to improve lung functions (+2.65% annual rate
of change of FEV1% predicted). TPE could be an important strategy to stabilize lung function.
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Résumé – Amélioration des fonctions pulmonaires grâce à un programme multidisciplinaire d’éducation thé-
rapeutique dans une clinique pédiatrique de mucoviscidose. Introduction : L’atteinte pulmonaire reste la cause
principale de morbidité et de mortalité dans la mucoviscidose. Le drainage du mucus par la physiothérapie respiratoire
est un élément clé du traitement. Le traitement quotidien est lourd, avec drainage autogène, inhalations de médicaments
ainsi que de nombreux traitements à prendre tout au long de la journée. La charge quotidienne engendre des conflits
intrafamiliaux et un stress important. La compliance au traitement est un enjeu majeur qui influence l’eﬃcacité de la
physiothérapie et des inhalations. Objectifs : L’objectif est de créer une structure d’éducation thérapeutique au sein de
notre consultation pédiatrique de mucoviscidose et de l’évaluer. Méthode : étude interventionnelle ouverte chez des
patients de ≥ 6 ans. Les patients ont été suivis au rythme habituel, chaque 3 mois pendant 2 ans. Une séance d’éduca-
tion thérapeutique se faisait à chaque consultation, soit par le médecin en charge de la consultation, soit par l’infirmière
référente. À la 1e visite, un contrat éducatif est défini avec le patient. Objectif primaire : évolution du VEMS et du
VEF25-75%. Objectifs secondaires : Évaluation de la connaissance de la maladie et de la qualité de vie des patients
(CFQr©). À la fin de l’étude, la connaissance des patients a été testée pour les aspects nutritionnels de la maladie dans
le groupe étudié. Résultats : Sur 32 patients éligibles, 17 ont acceptés l’étude. Le VEMS% prédit a augmenté de 5,3 %
dans le groupe intervention.
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Conclusion : L’utilisation d’un programme d’éducation thérapeutique permet un gain net sur les fonctions pulmonaires
(gain annuel du VEMS de +2,65 %). L’éducation thérapeutique semble être une stratégie importante pour la stabilisation
des fonctions pulmonaires.
Mots clés : mucoviscidose / enfant / éducation thérapeutique / fonctions pulmonaires / qualité de vie
Abbreviations: ATS: American thoracic society, BMI: body mass index, CF: cystic fibrosis, CFCH: Swiss society
for cystic fibrosis, CFQ: cystic fibrosis questionnaire, ERS: European respiratory society, FEF: Forced Expiration
Flow, FEV1%: Forced Expiration Volume in 1s, expressed in %, GETHEM: Groupe de travail Education THErapeu-
tique et Mucoviscidose, IPCEM: institut de perfectionnement en communication et éducation médicales, RV: residual
volume, TPE: therapeutic patient education, QoL: quality of life, TLC: total lung capacity, VEF: volume expiration
flow, VEMS: volume flow measurement.
1 Introduction
Pulmonary disease remains the most common cause of
morbidity and mortality in cystic fibrosis (CF). Abnormal
airway surface liquid conducting to impaired mucociliary
clearance is the basis of lung disease and begins soon after
birth [1, 2]. Accumulation of thick mucus in the small bronchi
makes the nidus of inflammation and infection, leading to lung
destruction. The clearing of mucus by chest physiotherapy is a
major keystone of pulmonary treatment.
Daily therapy is time consuming, with respiratory therapy,
inhalation therapy and a lot of medications to be taken all day
long. Adherence to treatment is, as always, a keystone of eﬃ-
cacy of treatment and a main issue for morbidity and mortal-
ity. Treatment burden becomes quite always a reason for intra-
familial conflicts and stress.
Therapeutic patient education (TPE) consists in a way to
give more competences to patient and his family to understand
and deal with all aspects of his disease, integrated in everyday
life of the patient. TPE will change the hierarchy between pa-
tient and his medical staﬀ in order to involve patient and his
family in the medical decisions. It can be done by acquisition
of self-care and adaptation competences.
Educational diagnosis is the first step on the way to edu-
cation. Its purpose is to asses aspects of patient‘s life and per-
sonality; to identify the needs, attempts and projects; and to
evaluate its potentiality. During the 2nd step, an educational
contract is discussed with the patient and his family. After this
step, periods of training give the opportunity to acquire skills
discussed within the contract. Finally, competence testing is
used to analyze the progress and to go on with a new contract.
It is also the time point for professionals for self-criticism [3].
As CF is a chronic disease, it is predisposed to profit from
TPE due to its treatment modalities, which includes amongst
others in most patients daily respiratory physiotherapy inclu-
sive inhalation of medications. In addition, the eﬃcacy of
physiotherapy and inhalation are particularly dependent of the
compliance of the patient, and therefore dependent in parts of
the education of the latter.
The aim of our prospective study was the evaluation of the
implementation of TPE in our pediatric CF cohort. Our unit
was not making any “structured” TPE. The clinical team in-
cluded a pediatrician pneumologist, a pediatrician, a physio-
therapist, a dietetician a nurse and a social worker. Patients
were seen at least 4 times a year by the physician and by the
other professionals on demand. Two members of the team par-
ticipated to the IPCEM cursus in Paris and all team had super-
visions by the CF team in Nantes.
2 Methods
2.1 Study patients
All patient ≥ 6 yrs of age with confirmed diagnosis of CF
(two positive sweat tests [chloride > 60 mmol/l] or a genotype
with two identifiable CF-causing mutations), able to perform
acceptable-quality spirometry, were eligible to participate in
the study. There were no formal exclusion criteria.
2.2 Study design
This was an open interventional prospective study, con-
ducted at the pediatric CF consultation of the university hospi-
tal of Lausanne, Switzerland.
The goal of this study was to implement and to evaluate a
multidisciplinary program of therapeutic education in pediatric
CF patients. The study duration was determined for 2 years
time.
We used tools created and validated by the GETHEM
(Groupe de travail Education Therapeutique et Mucovisci-
dose) in France: they allow a large flexibility according to
needs and attempt of patients with an organized basis [4–6].
Those tools include flow sheets and some story board used
by the investigators, varying according to age groups of chil-
dren. They cover all CF fields (self-care skills: how to detect a
pulmonary exacerbation, adaptation of enzymes replacement
according to alimentation, respiratory care, hygiene; adapta-
tive skills: how to react in case of pulmonary exacerbation, in
case of midsummer heat, in case of dehydration, how to cope
with what other people think; genetics). Each flow sheet is
characterized by the age of children, duration of the interven-
tion and extra needs of material. We also used a CD developed
by the Swiss Society for Cystic Fibrosis (CFCH): “un voyage
à travers l’appareil digestif” dedicated for children, which ex-
plain digestion process and needs of enzyme substitution [7].
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Patients were followed on their regular 3-month basis in
the outpatient clinic, with an annual assessment according to
international guidelines [8]. There were no additional visits
scheduled. After medical assessment one person of the team
was leading an educational session with the patient and his
parents. At the first study visit, patient and CF team agreed
on an educational diagnosis. This first step allows grasping the
diﬀerent sides of the patient life and personality. It allows to
identify is needs, his potentiality and to take in account his
attempt.
This led to a contract. This allowed defining the content of
next visits, according to patient, family and CF team. Interven-
tional education by the CF physician and the CF nurse took
place at each visit. Those interventions were done together
with the child and his family, except for adolescent patients
where intervention was directed only to the patient. Assess-
ment using specific tools was done every 6 month.
2.3 Study objectives
The primary endpoint was the evolution of FEV1% pre-
dicted and FEF25-75% predicted in the intervention group.
The secondary objectives were the evolution of RV/TLC, data
on anthropometry, quality of life, needs for emergency antibio-
therapy (orally, inhaled or intravenous). At the end of the study
a knowledge questionnaire was used [9].
2.4 Lung function measurements
Pulmonary function testing was conducted according to
ATS/ERS guidelines [10] at all visits. Results of FEV1%
predicted were classified according to the ATS/ERS guide-
lines [11].
2.5 Anthropometry
Weight, height and body-mass-index (BMI) were mea-
sured at all visits.
2.6 Quality of life (QoL) (CFQr©) [12,13]
Health-related QoL was measured using the Cystic
Fibrosis Questionnaire (CFQr©) at first and last visit [13].
2.7 Use of emergency antibiotherapy
(orally, inhaled or intravenous)
During the study period, the need for emergency antibio-
therapy (oral, inhaled or intravenous) for pulmonary exacerba-
tion (“rescue medication”) was noted at all visits.
2.8 Knowledge questionnaire
The knowledge concerning nutrition and pancreatic en-
zymes was addressed at the final visit using the questionnaire
developped by Stapleton et al. [9]. This score of knowledge
ranges from 0 to 28, the higher the score the better the knowl-
edge. We used only this topic as we couldn’t find any other
validated questionnaire. Our population was to small to allow
a validation of a new questionnaire.
2.9 Statistical analysis
The evolution of FEV1% during the study period was com-
pared by means of two-tailed t-tests. The same method was
applied to compare the evolution of FEV1% the 2 years pre-
ceding the baseline visit of the study (visit 1). Prior to analysis,
evolution of FEV1% was z-score transformed. A z-score is the
deviation from the sample mean expressed as number of stan-
dard deviations (SD).
2.10 Ethics
The study was approved by the local ethics committee at
the university of Lausanne. Informed written consent was ob-
tained prior to inclusion.
3 Results
The study was conducted between January 2007 and Jan-
uary 2009.
3.1 Patient demographics
Of 32 patients eligible to participate, 17 patients (11 males)
were willingly to participate and were therefore included. Age
was from 6 years up to 16 years (median age 11). Patient’s
demographics at visit 1 are shown in the Table I.
Most of the patients were asking for the nutritional and en-
zyme therapy aspects of the disease (14 patients, 82.4%), other
interest were: “Why do I take pills” (10, 58.9%), hygiene (6 pa-
tients, 35.3%), “how to deal myself with treatment” (5 patients,
29.4%) and genetics issues (4, 23.5%). Some topics were con-
sidered as fundamental and were proposed to all patients once
a year (risk of dehydration, how to detect a pulmonary exac-
erbation). Adolescent patients were more interested in the ge-
netics aspects.
3.2 Lung function
Two years before beginning of the study, 88% of patients
in the intervention group had a normal FEV1% predicted, 6%
a moderately severe disease (FEV1%: 70–89% of predicted)
and 6% a severe disease (FEV1% < 40%).
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Table I. Patients demographics at visit 1. Table shows characteris-
tics of patients in both groups at inclusion. Most patients had nor-
mal or mildly decreased lung functions. Only one patient had severe
lung disease. – Caractéristiques des patients à l’inclusion. Le tableau
montre les caractéristiques des patients à l’inclusion. La plupart des
patients avaient des fonctions pulmonaires normales ou légèrement




Age median in years (range) 11.0 (5.6–14.8)






– moderately severe 0
- severe 6%
– very severe 0
Between the beginning and the end of the study period,
FEV1% increased by a mean of 0.36 SD in the study group
(two-tailed paired t-test: p = 0.028). For the FEF25-75%,
evolution was positive with a mean fall of 8.3% in the study
group. However, this result was not conclusive (paired t test:
p = 0.118). For RV/TLC there was also a benefit, with a mean
fall of 25.2% in the intervention group .This result is again not
conclusive (p = 0.100) (Fig. 1).
Considering the time span between 2 years before inter-
vention until the end of the intervention study FEV1% pre-
dicted had a mean fall of 0.14 SD in the intervention group
(Fig. 1). FEF25-75% had a mean decrease of 2.8% in the
intervention group (Fig. 1). RV/TLC decreased of 57.07%
(p < 0.001)(Fig. 1).
3.3 Anthropometry
Mean weight at beginning of study was of 33.4 kg. Gain of
weight on the study time was of 6.4 kg in the study group.
Mean size at beginning of study was of 139.9 cm. Gain of
height on the study time was of 9.0 cm in the study group.
3.4 Number of emergency hospitalization /
use of oral rescue antibiotics
During the study period, patients were hospitalized a mean
time of 3.5 days pro 6 month period in the study group. Only
two patients had a decrease of hospitalization time in the study
group.
They took 23.2 days of oral rescue antibiotic therapy. Six
patients decreased their antibiotic needs over study time.
3.5 Knowledge questionnaire
Scores obtained were between 22 and 28 (between 78.6%
and 100% of correct answer). Median was 26 and mean 25.9
(92.5% of correct answers). For comparison, in the Stapleton
study, mean correct score was 54% between 5 and 8 years and
72% between 9 and 12 years old children [9]. It was not pos-
sible to make statistical correlations between those results and
the gain in lung functions because of the low number of pa-
tients. Nevertheless, all patients had a better knowledge score
than shown in the original article by Stapleton.
TPE is a long term process, and adherence to treatment
is not only (unfortunately) understanding of treatment. Some
patients were able to explain very clearly how and why to use
pancreatic extract but were not yet able to change their way of
doing.
3.6 Quality of life (QoL) (CFQr©)
It was not possible to sort out a trend in either items of the
CFQr© questionnaire.
4 Discussion
Using TPE, there was a clear trend to improve lung func-
tions (+2.65% annual rate of change of FEV1% predicted)
as well as disease-knowledge. Lack of statistical significance
in some clinically relevant associations is likely to be due to
the small sample size. In motivated patients and families, TPE
could be an important strategy to stabilize lung function.
TPE can help to solve adherence diﬃculties by a better
disease understanding as well as a more responsible position
of the patient (“understanding better to act better” [3]). This
will probably induce a change over time in most treatment is-
sues, with, at the end changes in some physical parameters,
as lung functions. FEV1% was about 10% better in the inter-
vention group 2 years before start of the study, moreover, all
pulmonary testing parameters were getting worst in the inter-
vention group before inclusion. The finding of a more impor-
tant decrease in the intervention group who had better FEV1%
(≥90%) in the two-years period prior to the study is coherent
with the recent findings by de Boeck et al who described a
significant higher annual rate of decline of 1.9% predicted in
a group of individuals with an FEV1% ≥90% predicted com-
pared with 0.4% predicted in a group with FEV1% < 90%
predicted [14]. In this regard of a faster decline of FEV1%
predicted in the intervention group prior to the intervention,
with an improvement during the study period, most likely due
to the intervention (TPE), becomes even more important.
Skills acquisitions on nutritional issues and pancreatic en-
zyme substitution were made by two diﬀerent supports: one
tool from the GETHEM (“Expliquer le rôle du pancréas dans
la digestion des graisses. Identifier le mode d’action des en-
zymes pancréatiques” with a true/false questionnaire) [14] and
a CD (“Un voyage à travers l’appareil digestif ” [7]).
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Figure 1. Evolution of pulmonary function during intervention and on a 2 years period before the beginning of the study. Considering the time
span between 2 years before intervention until the end of the intervention study, FEV1% predicted had a mean increase of 0.11 SD (paired
t-test: p = 0.685), FEF 25–75% had a mean decrease of 2.8% (p = 0.636) and VR/CPT a mean decrease of 57.07% (p < 0.001). – Évolution
des fonctions pulmonaires durant l’intervention et sur une période de 2 ans avant le début de l’étude. Sur la période totale, le VEMS prédit a
augmenté de 0,11 DS en moyenne (t-test apparié: p = 0,685), le DEM 25–75 % a diminué de 2,8 % (p = 0,636) et le VR/CPT a diminué de
57,07 % en moyenne (p < 0,001).
In regards of quality of life, no trend was seen in the CFQr©.
It seems that a longer time of study would be necessary but
even with such an intervention; the burden of the disease is
always present.
There was as well no significant diﬀerence in emergency
hospitalizations respectively use of rescue antibiotics (neither
orally nor inhaled), probably due to the short term of study
and by the fact that all patients were followed regularly at least
three-monthly and as needed.
At beginning of the study, there were no dietitian fix ac-
corded to the consultation, reason why it was planned initially
to have a dietitian involved for those in the intervention group.
However, due to circumstances not related to the study, a fix
CF-dietitian was us accorded for all patients, reason why it
would have been unethical to deprive the patients not in the in-
tervention group from the regularly follow-up by the dietitian.
The weak point in our study is certainly the lack of a ran-
domized control group, and the number of children recruited
was too small to allow adjusting for confounding variables in
multiple regressions. However, the same multi-disciplinary ap-
proach was continued in all other patients than those partici-
pating in the intervention group, without depriving them from
the “as usual” therapeutic education according to international
guidelines [8]. We clinicians probably overestimate to often
our impact when there are no objective measurements (“bench
marketing”) available [15]. The link between acquired skills
and change in way of doing (or being) is a key issue, but dif-
ficult to show. It was quite astonishing to see some patients
not able to go from the cognitive level to the practical level
(“how to change my habits). Nevertheless, we are sure that
things are changing with the time. Compliance was not as-
sessed in this study. In conclusion, a system of TPE might
stabilize lung function parameters in interested patients and
family. Although there is a lack of a randomized control group
in our study, it seems important to at least standardize TPE in
CF consultations.
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